EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta‐analysis of economic evaluation studies

Chayutthaphong Chaisai iD, Chanthawat Patikorn, Kednapa Thavorn, Shaun Wen Huey Lee, Nathorn Chaiyakunapruk iD, Sajesh K Veettil

Addiction · 2024

DOI: 10.1111/add.16464 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Addiction, 2024. Verfasst von Chayutthaphong Chaisai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Monash University Malaysia, Selangor, Malaysia. Hauptthemen laut MEDLINE: Varenicline, Smoking Cessation, Cost-Benefit Analysis, Smoking Cessation Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To conduct a systematic review and meta‐analysis and pool the incremental net benefits (INBs) of varenicline compared with behaviour support with bupropion or nicotine replacement therapy (NRT), behaviour support alone and unaided cessation in adult smokers making a first‐time attempt to quit.

Methods

A search for economic evaluation studies was conducted from inception to 30 September 2022, on PubMed, Embase, Cost‐Effectiveness Analysis (CEA) Registry by Tufts Medical Centre, EconLit and the NHS Economic Evaluation Database (NHS EED). Eligible studies were included if they were (1) conducted among adults ages 18 years old and older who were smokers attempting to quit for the first time; (2) compared varenicline to behaviour support with bupropion or NRT, behaviour support alone and unaided cessation; and (3) performed a CEA or cost‐utility analysis. The INBs were calculated and pooled across studies stratified by country income level and study perspective using the random‐effects model. Statistical heterogeneity between studies was assessed using the I 2 statistic and Cochrane Q statistic.

Results

Of the 1433 identified studies, 18 studies were included in our review. Our findings from healthcare system/payer perspective suggested that the use of varenicline is statistically significantly cost‐effective compared with bupropion (pooled INB, $830.75 [95% confidence interval, $208.23, $1453.28]), NRTs ($636.16 [$192.48, $1079.84]) and unaided cessation ($4212.35 [$1755.79, $6668.92]) in high‐income countries. Similarly, varenicline is also found to be cost‐effective compared to bupropion ($2706.27 [$1284.44, $4128.11]), NRTs ($3310.01 [$1781.53, $4838.50]) and behavioural support alone ($5438.22 [$4105.99, $6770.46]) in low‐ and middle‐income countries.

Conclusion

Varenicline is cost‐effective as a smoking cessation aid when compared with behavioural support with bupropion or nicotine replacement therapies and behavioural support alone in both high‐income countries and low‐ and middle‐income countries, from the healthcare system/payer perspective in adult smokers who attempt to quit for the first time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VareniclineSmoking CessationCost-Benefit AnalysisSmoking Cessation AgentsBupropionHumansTobacco Use Cessation DevicesBehavior TherapyAdult

Stichwörter der Autor:innen

economic evaluationincremental net monetary benefitpharmacoeconomicpharmacotherapy in smokingsmoking cessationvarenicline

Substanzen

VareniclineSmoking Cessation AgentsBupropion

Autor:innen und Institutionen

  • School of Pharmacy, Monash University Malaysia, Selangor, Malaysia.
  • Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA.
  • Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

ORCID-Profile: Chayutthaphong Chaisai, Nathorn Chaiyakunapruk

Zitieren

APA

Chaisai, C., Patikorn, C., Thavorn, K., Lee, S. W. H., Chaiyakunapruk, N., & Veettil, S. K. (2024). Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta‐analysis of economic evaluation studies. Addiction. https://doi.org/10.1111/add.16464

Vancouver

Chaisai C, Patikorn C, Thavorn K, Lee SWH, Chaiyakunapruk N, Veettil SK. Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta‐analysis of economic evaluation studies. Addiction. 2024. doi:10.1111/add.16464

BibTeX
@article{Chaisai2024,
  author = {Chaisai, Chayutthaphong and Patikorn, Chanthawat and Thavorn, Kednapa and Lee, Shaun Wen Huey and Chaiyakunapruk, Nathorn and Veettil, Sajesh K},
  title = {Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta‐analysis of economic evaluation studies},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16464}
}
Kostenlos starten →